Research News

Summaries of newly published research, clinical trial updates, and compound news.

CagriSema Explained: Novo Nordisk’s Semaglutide-Plus-Amylin Answer to Tirzepatide

GLP1Place Staff / January 15, 2026

Novo Nordisk filed CagriSema with the FDA in December 2025, backed by REDEFINE trial data showing 22.7% average weight loss. Here’s how the semaglutide-plus-amylin combination actually works.

FDA Approves the Wegovy Pill: The First Oral Semaglutide Built for Weight Loss

GLP1Place Staff / January 6, 2026

The FDA approved the Wegovy pill — oral semaglutide 25mg — on December 22, 2025, delivering 16.6% average weight loss in the OASIS 4 trial. Here’s how it differs from Rybelsus and Lilly’s rival Foundayo.

← Previous 1 … 3 4

Research Tools

GLP1Place

Independent educational research hub for GLP-1 receptor agonists, research peptides, and nootropic compounds. Not medical advice.

Compound data is sourced from published research and public literature. Always verify independently. See full disclaimer.

Scroll to Top